Biotech Values

[ignatiusrielly35]

Dew, your scenario doesn’t address what ADXS is getting in return for swapping the warrants out. The selling restriction would be unnecessary without the swap because those new shares wouldn’t exist. It seems to me that the warrant holders that were not offered the 1:1 swap simply were not part of whatever the other warrant holders might have agreed to provide in return, pursuant to your scenario. But they had to lower the exercise price for them anyway due to the MFN clause. Thoughts?